The Leader in
Transcatheter Mitral
Valve Repair Technology

Breakthrough TMVr Therapy
for High-Surgical-Risk Patients

MitraClip is the world’s first transcatheter mitral valve repair (TMVr) therapy that delivers a treatment option for patients with mitral regurgitation who would otherwise go untreated.¹,²

Over 70,000 patients worldwide* have been treated with MitraClip therapy, with 17,000 patients† followed through multiple studies and registries.

*Worldwide data as of November 2018, on file at Abbott.
Total patients from Abbott sponsored studies, TVT registry, TRAMI, Reshape HF2,
Matterhorn, Mitra-FR, GRASP.


Minimally Invasive Procedure

The MitraClip procedure is a minimally invasive catheter-based therapy performed by multidisciplinary Heart Teams.1 Open-heart surgery to repair or replace the mitral valve is generally recommended, but it is not an option for many patients.

TMVr with MitraClip therapy delivers a treatment option for patients who are not good surgical candidates.1-3

  • Corrado Tamburino discusses MitraClip therapy
    Interventional Cardiologist/Cardiologist, University of Catania, Italy

    “We can tailor the therapy patient by patient, giving a very low risk therapy with a high benefit result.”

AP2947039-WBO Rev. A

  1. MitraClip NTR XTR Clip Delivery System Instructions for Use.
  2. Lim DS, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after the transcatheter mitral valve repair. J Am Coll Cardiol. 2014;64(2):182-192.
  3. Baumgartner H, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease: The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J.2017;38(21):2739-2791.

This site uses cookies to improve your experience.

To find out more please read our Privacy and Cookies policy.



Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.